<?xml version='1.0' encoding='utf-8'?>
<document id="22607774"><sentence text="Could piracetam potentiate behavioural effects of psychostimulants?" /><sentence text="Press and internet reports mention abuse of nootropic drug piracetam (PIR) in combination with psychostimulants methamphetamine (MET) or 4-methylenedioxymethamphetamine (MDMA)"><entity charOffset="112-127" id="DDI-PubMed.22607774.s2.e0" text="methamphetamine" /><entity charOffset="129-132" id="DDI-PubMed.22607774.s2.e1" text="MET" /><entity charOffset="137-168" id="DDI-PubMed.22607774.s2.e2" text="4-methylenedioxymethamphetamine" /><entity charOffset="170-174" id="DDI-PubMed.22607774.s2.e3" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e0" e2="DDI-PubMed.22607774.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e0" e2="DDI-PubMed.22607774.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e0" e2="DDI-PubMed.22607774.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e0" e2="DDI-PubMed.22607774.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e1" e2="DDI-PubMed.22607774.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e1" e2="DDI-PubMed.22607774.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e1" e2="DDI-PubMed.22607774.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e2" e2="DDI-PubMed.22607774.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22607774.s2.e2" e2="DDI-PubMed.22607774.s2.e3" /></sentence><sentence text=" These combinations are believed to produce more profound desirable effects, while decreasing hangover" /><sentence text=" However, there is a lack of valid experimental studies on such drug-drug interactions in the scientific literature available" /><sentence text=" Our hypothesis proposes that a functional interaction exists between PIR and amphetamine psychostimulants (MET and MDMA) which can potentiate psychostimulant behavioural effects"><entity charOffset="78-89" id="DDI-PubMed.22607774.s5.e0" text="amphetamine" /><entity charOffset="108-118" id="DDI-PubMed.22607774.s5.e1" text="MET" /><entity charOffset="116-126" id="DDI-PubMed.22607774.s5.e2" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s5.e0" e2="DDI-PubMed.22607774.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s5.e0" e2="DDI-PubMed.22607774.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22607774.s5.e0" e2="DDI-PubMed.22607774.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22607774.s5.e1" e2="DDI-PubMed.22607774.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22607774.s5.e1" e2="DDI-PubMed.22607774.s5.e2" /></sentence><sentence text=" Our hypothesis is supported by the results of our pilot experiment testing acute effects of drugs given to mice intraperitoneally (Vehicle, n=12; MET 2"><entity charOffset="147-150" id="DDI-PubMed.22607774.s6.e0" text="MET" /></sentence><sentence text="5mg/kg, n=10; MDMA 2"><entity charOffset="14-16" id="DDI-PubMed.22607774.s7.e0" text="MDMA" /></sentence><sentence text="5mg/kg, n=11; PIR 300 mg/kg, n=12; PIR+MET, n=12; PIR+MDMA, n=11) in the Open Field Test (Actitrack, Panlab, Spain)"><entity charOffset="39-42" id="DDI-PubMed.22607774.s8.e0" text="MET" /><entity charOffset="54-57" id="DDI-PubMed.22607774.s8.e1" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s8.e0" e2="DDI-PubMed.22607774.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s8.e0" e2="DDI-PubMed.22607774.s8.e1" /></sentence><sentence text=" PIR given alone caused no significant changes in mouse locomotor/exploratory behaviour, whereas the same dose combined with either MET or MDMA significantly enhanced their stimulatory effects"><entity charOffset="132-135" id="DDI-PubMed.22607774.s9.e0" text="MET" /><entity charOffset="139-142" id="DDI-PubMed.22607774.s9.e1" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s9.e0" e2="DDI-PubMed.22607774.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s9.e0" e2="DDI-PubMed.22607774.s9.e1" /></sentence><sentence text=" Different possible neurobiological mechanism underlying drug-drug interaction of PIR with MET or MDMA are discussed, as modulation of dopaminergic, glutamatergic or cholinergic brain systems"><entity charOffset="91-94" id="DDI-PubMed.22607774.s10.e0" text="MET" /><entity charOffset="98-101" id="DDI-PubMed.22607774.s10.e1" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s10.e0" e2="DDI-PubMed.22607774.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s10.e0" e2="DDI-PubMed.22607774.s10.e1" /></sentence><sentence text=" However, the interaction with membrane phospholipids seems as the most plausible mechanism explaining PIR action on activities of neurotransmitter systems" /><sentence text=" Despite that our behavioural experiment cannot serve for explanation of the pharmacological mechanisms of these functional interactions, it shows that PIR effects can increase behavioural stimulation of amphetamine drugs"><entity charOffset="204-215" id="DDI-PubMed.22607774.s12.e0" text="amphetamine" /></sentence><sentence text=" Thus, the reported combining of PIR with MET or MDMA by human abusers is not perhaps a coincidental phenomenon and may be based on existing PIR potential to intensify acute psychostimulant effects of these drugs of abuse"><entity charOffset="42-52" id="DDI-PubMed.22607774.s13.e0" text="MET" /><entity charOffset="49-59" id="DDI-PubMed.22607774.s13.e1" text="MDMA" /><pair ddi="false" e1="DDI-PubMed.22607774.s13.e0" e2="DDI-PubMed.22607774.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22607774.s13.e0" e2="DDI-PubMed.22607774.s13.e1" /></sentence><sentence text="" /></document>